Exelixis
EXEL
#1688
Rank
A$15.56 B
Marketcap
$54.52
Share price
2.24%
Change (1 day)
65.50%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Cash on Hand

Cash on Hand as of September 2024 : A$1.82 Billion

According to Exelixis's latest financial reports the company has A$1.82 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Exelixis - Cash on Hand chart (from 2000 to 2024)

Cash on Hand by year

Year Cash on Hand Change
2023-12-31A$1.46 B-24.02%
2022-12-31A$1.92 B-4.98%
2021-12-31A$2.02 B28.97%
2020-12-31A$1.56 B28.91%
2019-12-31A$1.21 B23.68%
2018-12-31A$0.98 B98.15%
2017-12-31A$0.49 B-14.71%
2016-12-31A$0.58 B153.96%
2015-12-31A$0.22 B30.07%
2014-12-31A$0.17 B-35.14%
2013-12-31A$0.27 B-31.35%
2012-12-31A$0.39 B108.97%
2011-12-31A$0.18 B18.31%
2010-12-31A$0.16 B-29.17%
2009-12-31A$0.22 B-39.22%
2008-12-31A$0.37 B19.75%
2007-12-31A$0.31 B36.87%
2006-12-31A$0.22 B11.71%
2005-12-31A$0.20 B1.3%
2004-12-31A$0.20 B-37.13%
2003-12-31A$0.31 B-19.05%
2002-12-31A$0.39 B-11.69%
2001-12-31A$0.44 B121.64%
2000-12-31A$0.20 B1817.12%
1999-12-31A$10.5 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
A$6.58 B 261.49%๐Ÿ‡ฌ๐Ÿ‡ง UK
A$11.15 B 512.54%๐Ÿ‡ซ๐Ÿ‡ท France
A$22.34 B 1,127.17%๐Ÿ‡บ๐Ÿ‡ธ USA
A$12.39 B 580.65%๐Ÿ‡บ๐Ÿ‡ธ USA
A$13.79 B 657.76%๐Ÿ‡บ๐Ÿ‡ธ USA
A$31.07 B 1,606.84%๐Ÿ‡บ๐Ÿ‡ธ USA
A$15.23 B 736.89%๐Ÿ‡บ๐Ÿ‡ธ USA
A$43.41 M-97.62%๐Ÿ‡บ๐Ÿ‡ธ USA
A$0.11 B-93.49%๐Ÿ‡บ๐Ÿ‡ธ USA